z-logo
open-access-imgOpen Access
Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction
Author(s) -
Potter S.,
Trickey A.,
Rattay T.,
O'Connell R. L.,
Dave R.,
Baker E.,
Whisker L.,
Skillman J.,
Gardiner M. D.,
Macmillan R. D.,
Holcombe C.
Publication year - 2020
Publication title -
british journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.202
H-Index - 201
eISSN - 1365-2168
pISSN - 0007-1323
DOI - 10.1002/bjs.11468
Subject(s) - medicine , mastectomy , mammaplasty , breast reconstruction , surgery , demographics , total mastectomy , breast cancer , cancer , sociology , demography
Background Therapeutic mammaplasty (TM) may be an alternative to mastectomy, but few well designed studies have evaluated the success of this approach or compared the short‐term outcomes of TM with mastectomy with or without immediate breast reconstruction (IBR). Data from the national iBRA‐2 and TeaM studies were combined to compare the safety and short‐term outcomes of TM and mastectomy with or without IBR. Methods The subgroup of patients in the TeaM study who underwent TM to avoid mastectomy were identified, and data on demographics, complications, oncology and adjuvant treatment were compared with those of patients undergoing mastectomy with or without IBR in the iBRA‐2 study. The primary outcome was the percentage of successful breast‐conserving procedures in the TM group. Secondary outcomes included postoperative complications and time to adjuvant therapy. Results A total of 2916 patients (TM 376; mastectomy 1532; mastectomy and IBR 1008) were included in the analysis. Patients undergoing TM were more likely to be obese and to have undergone bilateral surgery than those having IBR. However, patients undergoing mastectomy with or without IBR were more likely to experience complications than the TM group (TM: 79, 21·0 per cent; mastectomy: 570, 37·2 per cent; mastectomy and IBR: 359, 35·6 per cent; P  < 0·001). Breast conservation was possible in 87·0 per cent of patients who had TM, and TM did not delay adjuvant treatment. Conclusion TM may allow high‐risk patients who would not be candidates for IBR to avoid mastectomy safely. Further work is needed to explore the comparative patient‐reported and cosmetic outcomes of the different approaches, and to establish long‐term oncological safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here